METHODS AND COMPOSITIONS FOR THE TREATMENT OF PERSISTENT INFECTIONS AND CANCER BY INHIBITING THE PROGRAMMED CELL DEATH 1 (PD-1) PATHWAY

摘要

Disclosed is the use of an antibody that modulates Programmed Cell Death-I (PD-I) expression on T cells in the manufacture of a medicament for therapeutically treating cancer in a subject, wherein the antibody is an anti-Programmed Death Ligand 1 (PDLI) antibody, and wherein the subject has been selected after ex vivo measurement of the expression of PD-I on T cells in a biological sample from the subject after initial treatment of the subject with the antibody and wherein a decrease in PD-I expression indicated that the initial treatment was efficacious.